Following adeno-associated virus (AAV)-mediated transduction, cellular RNA preparations can be contaminated with AAV single-stranded DNA. The single-stranded DNA genome of recombinant AAV vectors can serve as an efficient, but undesirable, template for traditional reverse transcriptase-polymerase chain reaction (RT-PCR) methods. Consequently, recombinant AAV gene therapy presents a unique challenge to the design of sensitive and reliable methods to detect vector-derived mRNA. Several methods have been proposed to reduce the presence of single-and doublestranded vector DNA without compromising RNA specificity. For example, DNase I, although widely used, can be ineffective at completely removing the AAV single-stranded DNA genome. We have developed a sensitive real-time RNA-Specific reverse transcriptase PCR (RS-PCR) method that is independent of DNase I treatment. The RS-PCR method relies on the generation of a first-strand cDNA template using a primer with a linker sequence, X, at the 5 0 -end such that synthesis of second-strand cDNA incorporates the X-linker sequence into the cDNA template. The RS-PCR then utilizes forward and reverse primers targeting AAV vector sequence and the X-primer site, respectively, while a vector-specific Taqman probe makes sensitive real-time detection possible. We present data to validate the sensitivity and RNA specificity of the RS-PCR method and propose two unique endogenous control strategies by monitoring expression of both b-glucuronidase and endogenous cystic fibrosis transmembrane conductance regulator (CFTR). Finally, we demonstrate the utility of this new RS-PCR method in detecting recombinant AAV-CFTR expression, including, an in vitro transduction assay and methods to support both preclinical and clinical trials.
Introduction
Reverse transcriptase-polymerase chain reaction (RT-PCR) methods are among the most sensitive and easily quantifiable assays for mRNA expression analysis. [1] [2] [3] [4] However, RNA preparations for RT-PCR analysis are typically contaminated with cellular genomic DNA. Consequently, RNA preparations following an adenoassociated virus (AAV)-mediated transduction can also be contaminated with AAV single-stranded DNA (ssDNA) (eg from intracellular intact viral particles 5 ). Unfortunately, the ssDNA genome of recombinant adeno-associated virus (rAAV) vectors can serve as an efficient, but undesirable, template for traditional RT-PCR methods. 6 Therefore, rAAV gene therapy presents a unique challenge to the design of sensitive and reliable methods to detect vector-derived mRNA.
Several methods have been proposed to reduce the presence of contaminating genomic DNA in RNA preparations. The most popular method is to treat the RNA with RNase-free DNase. However, DNase is not 100% effective at completely removing all DNA contamination 7, 8 and is ineffective at removing the AAV ssDNA genome. 9 Furthermore, even high-quality DNase I (purified from bovine pancreas) can be contaminated with low levels of RNase resulting in degradation of RNA and a reduction in RT-PCR assay sensitivity. 7 Techniques such as the isolation of polyadenylated mRNA or restriction enzyme digestion of ssDNA 6 may reduce, but not eliminate, the potential for a confounding DNA-derived signal in traditional RT-PCR methods. Designing PCR primers that span introns can allow size differentiation of RNA versus DNA-derived products, 10, 11 but this technique is limited to RNAs that are spliced and requires substantial sequence information -still, the detection of pseudogenes is possible. 12 Similarly, primers can be designed to target the exon/exon junction. However, even with careful primer placement, the 3 0 end of the primer can still bind to its complement sequence and initiate extension. 7 Finally, PCR primers can be designed that target the 3 0 untranslated region junction with the polyadenylation tail of mRNA, but this limits detection to the 3 0 region of the mRNA. 13 All of these methods have limitations that prevent them from being both sensitive and RNA-specific.
The first step in any RT-PCR method is to generate complementary DNA (cDNA) from RNA. The theory behind the RNA-specific PCR (RS-PCR) is to generate a cDNA that contains a unique sequence tag (linker). The linker sequence is appended to the 5 0 end of the firststrand cDNA primer and is incorporated into the cDNA molecule during second-strand synthesis. This linker sequence can then be targeted as a primer site during the PCR amplification step, thus theoretically providing the means to distinguish RNA-dependent cDNA templates from DNA itself (eg AAV genomes) during PCR amplification.
When this basic technique was first introduced, it resulted in as much as a 100-fold specificity for RNA. 14, 15 However, the technique was quite laborious involving numerous enzyme incubation steps, not quantitative and still not completely specific for RNA. Significant modifications were introduced in 1993 16 to improve RNA specificity and ease of use. Most notably, a first-strand cDNA primer was designed that contained deoxyuridine residues. Treatment of the cDNA reaction with uracyl-N-glycosylase (UNG) prior to the PCR succeeded in degrading excess first-strand cDNA primer to prevent it from functioning as a PCR primer during the amplification step. Despite the noted increase in RNA specificity, this particular modification required an additional enzyme incubation step and resulted in a reduced sensitivity for RNA. In addition, signal detection relied on gel electrophoresis and slot-blot hybridization techniques.
The RS-PCR method presented herein represents a continued improvement of earlier methods. The cDNA synthesis step has been significantly simplified by combining the RNaseH incubation with second-strand cDNA synthesis. Similarly, UNG is included in the PCR master mix and UNG incubation has been incorporated into the thermal cycling protocol. Finally, we have taken advantage of real-time PCR detection systems to improve RS-PCR specificity, sensitivity, and precision. 17, 18 As illustrated in Figure 1 , first-strand cDNA is synthesized using an oligonucleotide primer with a 'Xlinker sequence' attached at the 5 0 -end. This oligonucleotide is modified to contain deoxyuridines. Following first-strand cDNA synthesis, the reaction is treated with RNaseH to degrade the RNA portion of the RNA:DNA hybrid. At the same time, a second primer is added to the reaction mixture. Utilizing this second primer, the enzyme reverse transcriptase synthesizes second-strand cDNA and incorporates the sequence X 0 , complementary to the synthetic X sequence which was introduced during first-strand cDNA synthesis. Since the PCR master mix contains UNG, during the first stage of the PCR cycle program UNG eliminates the X primer sequences from reverse-transcriptase-extended firststrand cDNA and degrades excess first-strand cDNA primer. PCR amplification is initiated by a generic Figure 1 Illustrated RS-PCR method detailing the fate of RNA molecules versus ssDNA (see text for details).
AAV-CFTR RNA-specific PCR CJ Gerard et al reverse PCR primer (eg X in Figure 1 ) that targets the incorporated X 0 -linker sequence mentioned above. In this model, the addition of the X-linker PCR primer site is blocked for both (+) and (À) sense ssDNA (eg rAAV vector DNA; Figure 1 ) and double-stranded DNA (ssDNA) (eg rAAV vector replicative forms 19 ). Specifically, the synthesis of second-strand cDNA from (+) ssDNA is blocked by the formation of the DNA:DNA duplex first-strand cDNA product -DNA:DNA duplexes are not a template for RNaseH. 20 For the (À) ssDNA, cDNA synthesis is blocked at the hybridization step of the first-strand cDNA primer. Since there is no denaturation step prior to the cDNA reaction, the synthesis of both first and second-strand cDNA from dsDNA is again prevented by the formation of the DNA:DNA duplex.
Using this strategy, we have developed a sensitive, RNA-specific, real-time PCR method (DNase-free) targeting transcripts from recombinant AAV-CFTR (cystic fibrosis transmembrane conductance regulator). This RS-PCR method is used to demonstrate dose-dependent mRNA expression from an AAV-CFTR vector in an in vitro transduction assay. As part of assay characterization, we demonstrate the RNA specificity of the RS-PCR method even in the presence of 10 5 copies of either (+) or (À) sense ssDNA molecules, or 10 5 copies of dsDNA molecules per cDNA reaction. Finally, we demonstrate how easily the RS-PCR method can be adapted to monitor the expression of endogenous controls such as b-glucuronidase and human endogenous CFTR.
Results/conclusion

RNA specificity
Since DNase can have a detrimental effect on mRNA recovery, we set out to design an assay that could unequivocally identify AAV expression without the need for a DNase treatment. Figures 2a-c illustrate the degree to which the RS-PCR method is specific for RNA as compared to equal copies of DNA. A set of samples was generated consisting of 10 5 copies of either plus or minus strand recombinant AAV vector-specific ssDNA molecules, 10 5 copies of dsDNA (linearized plasmid), or 10 5 copies of an in vitro transcribed synthetic RNA. All samples were spiked in a background of normal human lung total RNA. The threshold plot in Figure 2a demonstrates that, even after a DNase treatment, DNA-spiked samples can still result in a positive expression signal following a traditional RT-PCR method (random-hexamer-primed cDNA). While the residual DNA signal detected in the (À) ssDNA and dsDNA samples is only weakly positive (threshold cycle (Ct) at cycles 37-40), this level could still confound the detection of very low levels of legitimate expression in clinical samples.
The same four samples in Figure 2a were tested in the vector-specific RS-PCR method except without the DNase treatment which is a necessity for traditional RT-PCR (Figure 2b ). This vector-specific RS-PCR method specifically targets the synthetic polyadenylation signal of the recombinant AAV-CFTR vector during first-strand cDNA synthesis (primer¼'XB 0 rt(CF)' from Table 2 , see Figure 3 for location of oligonucleotides). Although the DNA-spiked samples are still positive using this method, the signal is significantly lower (greater Ct) than equivalent copies of synthetic RNA (DCt¼4-8). The signal from the DNA templates is potentially the result of the kinetics of DNA duplex melting and reassociation. For example, for the (+) strand ssDNA template, which has the same sense as the mRNA, first-strand cDNA synthesis does occur, but unlike an RNA:DNA hybrid RNaseH does not degrade the resulting dsDNA molecule. However, occasional dissociation of this dsDNA intermediary could permit the generation of secondstrand cDNA and consequently result in a positive PCR signal. Similarly, if the duplex DNA hybrid resulting from second-strand cDNA synthesis of the (À) strand ssDNA template dissociates, then a pseudo (+) strand AAV-CFTR RNA-specific PCR CJ Gerard et al ssDNA template could be created. This latter reaction can only occur during the limited incubation time after addition of the second-strand cDNA reaction reagents and possibly explains why the (+) strand ssDNA generates a stronger non-RNA-specific signal (approximately two cycles earlier) compared to the (À) strand ssDNA. The double-stranded plasmid DNA (dsDNA) is also positive according to the threshold plot of Figure 2b . However, this PCR signal is only detectable at more than 10 cycles later than equivalent copies of the synthetic RNA. This 10-cycle disparity possibly reflects the strong duplex potential of a 6.9 kbp double-stranded plasmid DNA molecule. Of particular importance is that in the RS-PCR method, 10 5 copies of synthetic RNA are detectable at a Ct of 24 -four cycles earlier than the signal from the (+) strand ssDNA.
Treating the samples in Figure 2b with DNase prior to the vector-specific RS-PCR method would no doubt reduce the DNA signal to at most the levels seen in the RT-PCR method of Figure 2a (above). However, to completely eliminate the possibility of a DNA-derived signal, we decided to target RNA-specific sequences in the first-strand cDNA reaction, namely, the polyadenylated tail of mRNA. To that end, a poly-A-specific firststrand cDNA primer ('XB 0 rt(T)', Table 2 ) was designed for the RS-PCR method.
In Figure 2c , the same four DNA and RNA samples in Figures 2a and b were analyzed in this poly-A-specific RS-PCR. In contrast to either the DNase-treated RT-PCR or the non-DNase-treated vector-specific RS-PCR, either the (+), (À) or dsDNA spikes are positive using the poly-A-specific RS-PCR method. The synthetic RNA spike, not being polyadenylated, generates only a weak signal compared to the vector-specific RS-PCR. This weak signal may be the result of nonspecific hybridization of the oligo-d(T/U) first-strand cDNA primer to the adenine-rich synthetic polyadenylation sequence. Note that since the DNA spikes are not positive and all of the spikes are in a background of total human lung RNA, it is apparent that the positive signal is specific for this particular synthetic RNA spike sequence.
Effect of UNG on RNA specificity UNG digestion of the cDNA product, prior to PCR cycling, degrades residual first-strand cDNA primers so that these oligonucleotides cannot function as DNAspecific primers during the PCR. To assess the removal of these dU-containing cDNA primers on RS-PCR specificity, the RS-PCR method was run with two variations of the same vector-specific first-strand cDNA primer, 'XB 0 rt(CF)'. One version (as indicated in Table 1 ) contained a mixture of deoxythymidines and deoxyuridines thereby making it susceptible to UNG digestion. An alternate oligo differed only in the replacement of all deoxyuridines with deoxythymidines and was therefore not a template for UNG.
In Figure 4 , note that without a UNG substrate (dT-only data) the Ct from the DNA spikes varies from 25.2 to 27.1 as compared to equivalent copies of the synthetic RNA spike (Ct¼23.8). However, when UNG activity removes residual first-strand cDNA primer following cDNA synthesis, the DNA-specific Ct's range from 32.9 to 35.1 (dT/U data). The Ct shift results in an increase in RNA specificity of 135 to 257-fold. Interestingly, the use of dUcontaining first-strand cDNA primers in combination with UNG digestion not only increases RNA specificity by at least 100-fold, but it may also increase RNA sensitivity almost two-fold (or 0.8 Ct). This increase in sensitivity could be explained by reduced competition for the 'X' reverse primer (Xpcr.rev) in the PCR step.
These data demonstrate that even without a DNase treatment, the RS-PCR method results in at least a 100-fold increase in affinity for an RNA template compared to a DNA template. The RS-PCR can become completely RNA-specific by targeting in the first-strand cDNA reaction RNA-specific sequences such as the poly-A tail of mRNA (Figure 2c ).
RNA sensitivity
The primary advantage of the RS-PCR is the increased specificity of the method for RNA in the absence of DNase treatment. However, for clinical gene therapy applications where vector expression levels are likely to be low, assay sensitivity cannot be sacrificed for the sake of specificity. The gold standard for sensitive expression analysis has long been the traditional RT-PCR where sensitivity on the order of 10 copies is possible. 4 We investigated whether a similar level of sensitivity could be achieved with the RS-PCR method.
A standard curve of in vitro-transcribed synthetic RNA was prepared by serial dilution into a background of total human lung RNA. Assay sensitivity for this standard curve was evaluated with the vector-specific RS-PCR protocol (using first-strand cDNA primer, 'XB 0 rt(CF)'). The threshold plot in Figure 5a indicates a sensitivity of at least two copies of template RNA. The Figure 5b demonstrates excellent linearity over six orders of magnitude and high PCR efficiency (91%). This level of sensitivity was also corroborated using mammalian cell culture-derived mRNA. Using the same vector-specific RS-PCR method, the standard curve in Figure 5b was used to quantitate the RNA copies per cell for a cell line expressing CFTR from an AAV2 vector construct (Cl37.5). Serial dilutions of AAV-CFTR RNA were analyzed -where they fell in the range of quantitation of the standard curve is indicated in Figure 5b . These data indicate 18 (73) copies of vector-specific mRNA per Cl37.5 cell. Cl37.5 total RNA was then diluted into normal human lung RNA to create standards consisting of approximately 180, 18, and 1.8 copies of CFTR vector RNA per PCR (standards I-III, containing 1 ng, 100 pg, and 10 pg of Cl37.5 RNA per 65 ml cDNA reaction, respectively; standard IV is human lung background RNA only). These Cl37.5 standards, containing AAV-CFTR cellular (polyadenylated) mRNA, were run in a poly-A-specific RS-PCR method (using first-strand cDNA primer, 'XB 0 rt(T)'). The threshold plot of these Cl37.5 standards (Figure 6 ) indicates that the 1.8-copy sample (standard III) has the same cycle Ct (40) as the two-copy in vitrotranscribed synthetic RNA. Repeated assay qualification runs of the Cl37.5 standards (I-IV) confirm that standard II (18 copies of AAV-CFTR vector mRNA) is positive 100% of the time whereas standard III (1.8 copies) is positive two-thirds of the time. These data are consistent with Poisson distribution statistics and suggest near single-copy sensitivity. Additionally, the choice of firststrand cDNA primer, either vector-specific for the synthetic RNA ( Figure 5 ) or poly-A-specific for Cl37.5 RNA (Figure 6 ), does not influence sensitivity.
RS-PCR applications and control strategies
A well-designed expression assay incorporates endogenous (eg ubiquitously expressed genes) and/or exogenous spike controls to monitor attributes such as RNA quantity, quality, or sample matrix inhibition. 4 The following data demonstrate how the RS-PCR method presented herein can be adapted to accommodate two different control strategies by targeting a product of firststrand cDNA synthesis, or both first-and second-strand cDNA synthesis.
In vitro transduction assay -first-strand cDNA control. An in vitro transduction assay was designed to demonstrate that the recombinant AAV-CFTR vector is functional in that it can transduce cells and express mRNA. As a control strategy to support this in vitro assay, we chose to monitor the expression of a typical housekeeping gene, b-glucuronidase (GUS). The detection of GUS mRNA is possible as the first-strand cDNA primer ('XB 0 rt(T)') generates first-strand cDNA from all polyadenylated mRNAs. The resulting product can function as a substrate during the PCR. Recall that since actual RNA specificity relies on the generation of a second-strand cDNA template, targeting a product of first-strand cDNA synthesis does not necessarily render the method RNA-specific. However, unambiguous RNA Figure 4 Effect of UNG on RS-PCR RNA specificity. The vector-specific first-strand cDNA primer 0 XB 0 rt(CF)' (see Table 1 ) contains either a mixture of dT/dU (a substrate for UNG) or only dT. The difference in Ct between the dT/dU method and the dT method can be used to calculate the fold increase in RNA specificity attributed to the activity of UNG (fold increase in RNA specificity is calculated as indicated in the Materials and methods). Note that the y-axis is reversed (a lower Ct indicates a stronger fluorescent signal than a higher Ct). All DNA and RNA samples are spiked into a background of normal human lung RNA. SynRNA¼in-vitro transcribed synthetic RNA spike, (+) ssDNA¼sense single-stranded DNA, (À) ssDNA¼antisense single-stranded DNA, dsDNA¼double-stranded DNA. Error bars indicate 7s.d. of triplicate PCRs. AAV-CFTR RNA-specific PCR CJ Gerard et al specificity is only critical for interpreting low levels of gene expression, such as from an rAAV transgene. Nonetheless, previous experience with these commercially available GUS RT-PCR reagents indicated that there was no detectable signal that could be attributed to genomic DNA (eg pseudogenes 21 ). The expression data in Figure 7 have been normalized to GUS and calibrated to the level of expression as detected in standard II (approximately 18 copies of AAV-CFTR mRNA as determined above; raw Ct data and method of expression normalization are summarized in Table 3 ). GUS Ct raw data are indicated on the secondary y-axis to emphasize the relative consistency in GUS expression across all samples. GUS cDNA, being a product of first-strand synthesis only, is useful in verifying the quality of mRNA but does not control for the AAV-CFTR-dependent second-strand cDNA synthesis. Nonetheless, the data clearly demonstrate that the level of AAV-CFTR expression is a function of the multiplicity of infection (DRP/cell), thus confirming the functionality of the AAV-CFTR vector.
Preclinical RS-PCR application -first-strand cDNA control. The capacity of the AAV-CFTR vector to infect lung cells and express mRNA in vivo is demonstrated in Figure 8 . For this study, rhesus monkeys were exposed to AAV-CFTR aerosol inhalation once every 3 weeks for 9 weeks and killed at day 63. Total RNA was processed from lung tissue and analyzed in the RS-PCR. AAV-CFTR expression was normalized to GUS and calibrated relative to standard II. There was clear AAV-CFTR expression in site 'b' of both animals one and two. The expression in animal one was approximately 10-fold above the 18-copy level of expression in standard II, whereas expression was likely close to single-copy level in animal two. This method, similar to the in vitro transduction assay, only monitors GUS first-strand cDNA as a surrogate for RNA quality and quantity. Consequently, the same limitations apply as those discussed above. However, the processing of whole tissue for RNA increases the sensitivity for detecting AAV-CFTR vector mRNA in vivo.
Clinical RS-PCR application -first-and second-strand cDNA controls. A main objective in developing an RNA-specific expression assay was to analyze RNA isolated from human lung brushings for AAV-CFTR expression to support a phase I clinical trial. Since RNA isolated from human lung brushings can be of particularly poor quality, we chose to monitor the expression of both the housekeeping gene GUS (described above) and endogenous CFTR (a product of second-strand synthesis) as controls for mRNA quantity and quality. By incorporating GUS into this clinical assay, we would be assured of having an mRNA control for those CFTR patients that might not express endogenous CFTR mRNA. 22 As discussed earlier, the poly-A-specific first-strand cDNA primer, XB'rt(T) (indicated in Figure 3) , will prime the synthesis of first-strand cDNA from all polyadenylated mRNA. Second-strand cDNA synthesis is primed by the A1 oligonucleotide, which is specific for both endogenous and AAV-CFTR cDNA. However, due to the presence of a large 3 0 untranslated sequence, PCR Figure 6 Standards (I-IV), serial dilutions of total RNA from Cl37.5 cells, confirm a minimum sensitivity of approximately two copies of AAV-CFTR mRNA when using the poly-A-specific RS-PCR method (firststrand cDNA primer, 'XB 0 rt(T)', from Table 1 ). To calculate copies of AAV-CFTR mRNA, each cell was assumed to have the equivalent of 15 pg of total RNA. Repeated qualification runs of the Cl37.5 total RNA standards (I-IV) confirm that standard II (18 copies of AAV-CFTR mRNA) is positive 100% of the time whereas standard III (1.8 copies) is positive two-thirds of the time. AAV-CFTR RNA-specific PCR CJ Gerard et al detection of the endogenous CFTR template requires the synthesis of over 1.6 kbp of second-strand cDNA as opposed to only about 200 bp for AAV-CFTR expression. We set out to determine a mathematical correction factor that we could use to compensate for the reduced synthesis efficiency of a 1.6 kbp cDNA PCR template. This would make it possible to not only run all PCR assays from a single cDNA reaction but would allow us to directly compare the expression levels of AAV-CFTR and endogenous CFTR after normalizing both to GUS. To determine a correction factor for detection of endogenous CFTR, a second-strand cDNA primer was designed that was specific for the 3 0 untranslated region of the endogenous CFTR mRNA (g1, see Figure 3 ) such that the second-strand cDNA product was the same size as the second-strand cDNA product from AAV-CFTR vector RNA. Likewise, we also designed a forward PCR primer and Taqman probe (CFg.for and CFg.tmp, respectively) for the specific detection of endogenous CFTR (see Figure 3) .
A total of nine human lung RNA samples were screened in the poly-A-specific RS-PCR method with both the A1 and g1 second-strand cDNA primers -four lung brushings, one commercial source of lung RNA, and standards I-IV, described above. The cDNAs were then analyzed for endogenous CFTR expression. Table 2 summarizes the Ct data comparing the endogenous CFTR expression from A1 versus g1-generated secondstrand cDNA. There was a median Ct difference of 2.14 cycles between the A1 and g1-generated cDNA templates. Assuming a PCR efficiency of 100% (a two-fold increase in PCR product with every cycle), a correction factor of 4.4-fold was calculated (¼2 2.14 ). With this correction factor it would be possible to PCR amplify endogenous CFTR and AAV-CFTR using product from the same A1-primed cDNA reaction and then directly compare expression levels of the two mRNAs. The data in Figure 9 demonstrate how endogenous CFTR and GUS expressions are used together to interpret the AAV-CFTR vector expression data from a set of eight human lung brushing RNAs. For all samples, both AAV-CFTR and endogenous CFTR expressions have been normalized to GUS and calibrated to the level of AAV-CFTR expression as measured in standard II -the calculations that go into evaluating relative expression are detailed in Table 3 . The GUS Ct is included on the secondary y-axis. Note the variability and generally poor quality of RNA isolated from clinical lung brushings. Almost all of the GUS Ct's for the lung brushings are at least 3 Ct's greater than the GUS Ct's of the control RNAs (standards I-IV). This indicates approximately 10-fold less amplifiable mRNA in the lung brushings as compared to the control RNAs. Given mRNA of this quality it is no surprise that AAV-CFTR vector-specific expression is not detected in these eight samples and highlights sample collection methods as a challenge for future trials. A detailed summary of the results of this phase I AAV-CFTR clinical trial has been published elsewhere. 23 Summary. In summary, we have demonstrated that the RS-PCR is an effective method to detect low-level expression of a target gene in a potentially high background of ssDNA (eg from AAV vector). This specificity is achieved even in the absence of a DNase treatment. We have demonstrated that the assay can achieve near single-copy sensitivity and is amenable to Figure 9 A phase I, single administration, dose escalation trial was designed and executed to assess safety and delivery of tgAAVCF, and AAV vector encoding the human CFTR cDNA, by nebulization to the lungs of CF subjects. Bronchial wash fluid RNA was processed using the Qiagen RNeasy method. AAV-CFTR and endogenous CFTR expressions were normalized to GUS and calibrated relative to the 18-copy Cl37.5 standard. GUS Ct is indicated on the alternate y-axis.
AAV-CFTR RNA-specific PCR CJ Gerard et al multiple control strategies by targeting products of firststrand cDNA and/or second-strand cDNA synthesis. In addition, we have recently discovered that the addition of DNA polymerase to the second-strand cDNA reaction can significantly improve sample reproducibility for some targets.
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This RS-PCR method effectively addresses concerns that have been expressed regarding the interpretation of mRNA expression data resulting from rAAV vector transductions. 6 Consequently, since its development, we have extensively used the RS-PCR for expression analysis following AAV vector transduction with a number of different rAAV vector constructs, including, factor VIII and TNFR:Fc (dimerized tumor necrosis factor receptor 24 ). However, the RS-PCR is also a flexible method and need not be limited to AAV gene therapy applications. Any traditional RT-PCR method that requires sensitivity and unequivocal RNA specificity could benefit from the application of the RS-PCR as long as PCR primers are designed within close proximity to the poly-adenylation signal. The poly-A-specific version of the assay utilizes both a generic first-strand cDNA primer and reverse PCR primer. Applying the poly-Aspecific RS-PCR method to new targets requires only the design of a unique forward PCR primer, a second-strand cDNA primer and a Taqman probe. Of course, the method is also amenable to alternate real-time detection systems such as molecular beacons (Stratagene, La Jolla CA, USA), MGB Eclipse probes (Epoch Biosciences, Bothell, WA, USA), or Hybridization probes (Roche, Indianapolis, IN, USA).
Materials and methods
RNA isolation and cDNA synthesis
Total RNA was prepared from cell culture and tissue samples using the RNeasy method (Qiagen, Valencia, CA, USA). Additionally, all commercially available RNA was processed through the same RNeasy column. A quantity of 650 ng of total RNA was reverse transcribed into first-strand cDNA using the Gibco 'Superscriptt 
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AAV-CFTR RNA-specific PCR CJ Gerard et al First-Strand cDNA Synthesis System for RT-PCR' kit (Life Technologies, Rockville, MD, USA) in a total volume of 20 ml containing a cDNA primer (see Table  1 ) at a final concentration of 0.5 mM. First-strand cDNA synthesis was allowed to proceed for 50 min at 421C in a GeneAmp 9700 thermal cycler (Applied Biosytems, Foster City, CA, USA). Following first-strand cDNA synthesis, samples were temporarily transferred to the benchtop where 2 ml of second-strand cDNA master mix was added (Gibco; 10 Â RT buffer and magnesium chloride, as above, supplemented with 0.5 mM of second-strand cDNA primer (Table 1 ) and 1 U of RNaseH. Samples were then returned to the thermal cycler for an additional 40 min at 421C after which 43 ml of TE buffer (10 mM Tris, 1 mM EDTA, pH 8) was added and the cDNA (total volume 65 ml) was stored at 41C prior to PCR.
Real-time PCR and threshold cycles
Raw data from a real-time PCR are frequently viewed in threshold plots (eg Figure 2) . These graphs plot the increase in sample fluorescence versus cycle number during the PCR. The cycle number at which the fluorescence of a particular sample rises above background is commonly referred to as the threshold cycle or Ct. 17 
AAV-CFTR, endogenous CFTR, and GUS PCR
All PCRs contained the cDNA from 100 ng of total RNA (10 ml of 65 ml cDNA reaction, above) and were run in a described total volume of 50 ml using a commercially available pre-prepared 2 Â real-time PCR master mix (Applied Biosystems, Foster City, CA, USA). Primers and Taqman probes, as indicated in Table 1 , were used at a final concentration of 0.3 and 0.1 mM, respectively. The commercially available GUS PCR reagent was used according to the manufacturer's recommendations (Applied Biosystems, Foster City, CA, USA) -oligo sequences and concentrations are proprietary. All PCRs were done in a Sequence Detection System model 7700 real-time thermal cycler (Applied Biosystems, Foster City, CA, USA) according to the following program: 10 min at 501C, 10 min at 951C, followed by 50 cycles of 15 s at 951C and 1 min at 601C.
RNA specificity and sensitivity experiments
The AAV-CFTR-specific ssDNA spike was generated by T/A cloning a 450 bp PCR amplicon, containing the RS-PCR template sequence, into the pCR2.1 vector (Invitrogen, Carlsbad, CA, USA). The AAV-CFTR fragment was then subcloned into the phagemid vectors, pBluescript II KS(+) and KS(À). After infecting the phagemid culture with M13 helper phage, (+) and (À) ssDNA was purified from the supernatant using the Wizard M13 DNA Purification System (Promega, Madison, WI, USA). To generate the synthetic RNA, a T7 promoter sequence was added to a similar 450 bp PCR product using the Lign'-Scribe procedure (Ambion, Austin, TX, USA). Synthetic RNA was transcribed in vitro using the Ambion Megashortscript kit. All spiked samples are in a background of 100 ng of normal lung total RNA (Clontech, Palo Alto, CA, USA) per PCR. PCR efficiency is calculated based on the slope of a standard curve according to the following formula: percent efficiency¼(1À10 1/Àslope ) Â 100.
Clone 37.5 (Cl37.5) is a HeLa-based cell line that was stably transfected with plasmid DNA containing the AAV-CFTR vector sequence. Total RNA isolated from this cell line was used to make the RNA standards I-IV. For calculation of copies of AAV-CFTR mRNA, each cell was assumed to have the equivalent of 15 pg of total RNA. Repeated qualification runs of the Cl37.5 total RNA standards (I-IV) confirmed that standard II (18 copies of AAV-CFTR mRNA) was positive 100% of the time whereas standard III (1.8 copies) was positive twothirds of the time (data not shown). These data are in agreement with the RS-PCR limit-of-detection as determined by the in vitro-transcribed synthetic RNA, described above.
Uracyl-N-glycosylase efficiency
It was not possible to remove UNG from the preformulated PCR master mix. Therefore, to evaluate the efficacy of the UNG digestion with respect to RNA specificity, the cDNA reaction for the vector-specific RS-PCR was run with two different versions of the same first-strand cDNA primer ('XB 0 rt(CF)'): a d(T/U)-containing oligo and a d(T)-oligo. The fold increase in RNA specificity was calculated by the DCt method: 2^{Ct(dT/U-oligo) ÀCt(dT-oligo)}.
In vitro transduction assay COS-7 (ATCC CRL-1651) cells were plated at subconfluence in 12-well plates and incubated overnight at 371C and 5% CO 2 . At 24 h postplating, cells were aspirated and AAV-CFTR, which had been serially diluted in complete cell culture media from 1 Â 10 4 / to 1Â 10 1 DRP/cell, was added to the cells. Transduction at each dose of AAV-CFTR was done in triplicate cell culture wells. Transductions were incubated at 371C and 5% CO 2 for 48 h before cell harvest by trypsinization. Harvested cells were pelleted by centrifugation, washed with Dulbecco's phosphate-buffered saline and pellets frozen at À701C. After thawing the harvested cells, total RNA was isolated using the Qiagen RNeasy method.
Rhesus lung tissue
Rhesus monkeys (Macaca mulatta) were exposed to AAV-CFTR vector by aerosol inhalation once every 3 weeks for 9 weeks and killed at day 63. Harvested lung tissue was processed for total RNA using Qiagen RNeasy method. AAV-CFTR expression was normalized to GUS and calibrated relative to the 18-copy Cl37.5 standard (standard II). This study was conducted in accordance with 21 CFR, Part 58 (FDA Good Laboratory Practice Regulations).
Clinical lung brushings
A phase I, single administration, dose escalation trial was designed and executed to assess safety and delivery of tgAAVCF (AAV-CFTR), an AAV vector encoding the human CFTR cDNA, by nebulization to the lungs of CF subjects. 23 The study was conducted according to current Good Clinical Practice and approved by appropriate regulatory agencies. RS-PCR assays for both the rhesus study (above) and the clinical study were not conducted according to current Good Laboratory Practices. However, all assays were conducted according to Standard Operating Procedures and were documented as per GLPs. Briefly, bronchial wash fluid was collected as previously described 23 and RNA processed using the Qiagen RNeasy method. AAV-CFTR and endogenous CFTR expression were normalized to GUS and calibrated relative to the 18-copy Cl37.5 standard (standard II).
